Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03789721 · ClinicalTrials.gov registry record
Adrenoleukodystrophy National Registry Study
A clinical trial of Adrenoleukodystrophy and ALD (Adrenoleukodystrophy), sponsored by Masonic Cancer Center, University of Minnesota.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 1
- Study location
NCT03789721: Recruiting study of Adrenoleukodystrophy and ALD (Adrenoleukodystrophy), sponsored by Masonic Cancer Center, University of Minnesota.
NCT03789721 is a study of Adrenoleukodystrophy and ALD (Adrenoleukodystrophy) that is actively recruiting participants, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 1,000 participants, below the 2,055-participant average among 6 other Adrenoleukodystrophy trials with a reported enrollment target (51% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03789721, a study of Adrenoleukodystrophy and ALD (Adrenoleukodystrophy), is actively recruiting participants, sponsored by Masonic Cancer Center, University of Minnesota.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this registry to understand the natural history and disease progression in ALD and potentially develop bio-markers using the biospecimens collected using this registry.
Primary Outcome
Collect clinical and epidemiological data through medical record abstraction and self-reported questionnaire survey semi-annually.
Conditions Studied
Interventions
- OTHER Medical Record Abstraction
- OTHER Biospecimen Sample Collection
Study Locations (1)
Minnesota
- Masonic Cancer Center at University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2019-05-01 |
| Est. Completion | 2030-02 |
What NCT03789721 shows while recruiting
NCT03789721 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, below the 2,055-participant average among 6 other Adrenoleukodystrophy trials with a reported enrollment target (51% lower).
The record links to 3 conditions, with Adrenoleukodystrophy appearing as the primary indexed condition, and to 2 interventions - of which Medical Record Abstraction is the first listed.
NCT03789721 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT03789721 about?
NCT03789721 is a clinical study titled "Adrenoleukodystrophy National Registry Study". The aim of this registry to understand the natural history and disease progression in ALD and potentially develop bio-markers using the biospecimens collected using this registry.
What is the current status of trial NCT03789721?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2019-05-01. Estimated completion is 2030-02.
What conditions does trial NCT03789721 study?
This clinical trial studies the following conditions: Adrenoleukodystrophy, ALD (Adrenoleukodystrophy), Cerebral Adrenoleukodystrophy.
What interventions are being tested in trial NCT03789721?
The interventions under investigation include: Medical Record Abstraction (OTHER), Biospecimen Sample Collection (OTHER).
Who is sponsoring clinical trial NCT03789721?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03789721 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adrenoleukodystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Myelin Disorders Biorepository Project
RECRUITING
-
UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells
RECRUITING · Phase 1
-
Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy
ACTIVE NOT RECRUITING · Phase 4
-
Human Placental-Derived Stem Cell Transplantation
COMPLETED · Phase 1
-
Stem Cell Transplant for Inborn Errors of Metabolism
COMPLETED · Phase 2
-
Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI